ShanXi C&Y Pharmaceutical GroupLTD 관리

관리 기준 확인 4/4

ShanXi C&Y Pharmaceutical GroupLTD CEO는 Qun Zhao, Oct2021 에 임명되었습니다 의 임기는 3.08 년입니다. 는 CN¥ 119.41M 가치에 해당하는 회사 주식의 5.39% 직접 소유합니다. 119.41M. 경영진과 이사회의 평균 재임 기간은 각각 7.3 년과 4.8 년입니다.

주요 정보

Qun Zhao

최고 경영자

CN¥943.8k

총 보상

CEO 급여 비율	n/a
CEO 임기	3.1yrs
CEO 소유권	5.4%
경영진 평균 재임 기간	7.3yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet

Sep 30

ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues

May 27

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

Mar 25

ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Mar 06

CEO

Qun Zhao (53 yo)

3.1yrs

테뉴어

CN¥943,800

보상

Mr. Qun Zhao has been President of ShanXi C&Y Pharmaceutical Group Co., Ltd. since October 26, 2021 and its a Director since June 1, 2010. Mr. Zhao served as Chairman of the Board at ShanXi C&Y Pharmaceuti...

리더십 팀

이름	위치	테뉴어	보상	소유권
Qun Zhao	President & Director	3.1yrs	CN¥943.80k	5.39% CN¥ 119.4m
Yanjie He	Financial Director	6.2yrs	CN¥558.90k	데이터 없음
Junxian Yu	Secretary	8.3yrs	CN¥774.80k	0.42% CN¥ 9.2m
Ying Min Yu	Chief Engineer	8.3yrs	CN¥453.90k	0.030% CN¥ 669.8k

7.3yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: 300254 의 관리팀은 노련하고 경험 (평균 재직 기간 7.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Qun Zhao	President & Director	14.4yrs	CN¥943.80k	5.39% CN¥ 119.4m
Junxian Yu	Secretary	12.8yrs	CN¥774.80k	0.42% CN¥ 9.2m
Hairong Zhong	Vice Chairman	9.7yrs	CN¥668.30k	0.91% CN¥ 20.1m
Lequn Huang	Chairman	4.8yrs	CN¥89.40k	2.08% CN¥ 46.0m
Hao Gao	Independent Director	4.8yrs	CN¥60.00k	데이터 없음
Tao Ju	Independent Director	4.8yrs	CN¥60.00k	데이터 없음
Xuhong Zhang	Supervisor	14.4yrs	데이터 없음	데이터 없음
Guowen Wei	Supervisor	11.4yrs	데이터 없음	데이터 없음
Haibo Zhu	Supervisory Board Chairman	1.8yrs	데이터 없음	0.048% CN¥ 1.1m
Zhukun Lou	Independent Director	2.2yrs	CN¥60.00k	데이터 없음
Guowei Fang	Independent Director	1.4yrs	CN¥30.00k	데이터 없음

4.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 300254 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

ShanXi C&Y Pharmaceutical GroupLTD 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

ShanXi C&Y Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 09, 2024

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.044 (vs CN¥0.043 in 3Q 2023)

ShanXi C&Y Pharmaceutical Group Co.,LTD. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 25%

Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet

Second quarter 2024 earnings released: EPS: CN¥0.063 (vs CN¥0.091 loss in 2Q 2023)

Investor sentiment improves as stock rises 19%

New minor risk - Shareholder dilution

ShanXi C&Y Pharmaceutical Group Co.,LTD. to Report First Half, 2024 Results on Aug 29, 2024

ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues

Investor sentiment improves as stock rises 29%

Investor sentiment deteriorates as stock falls 23%

ShanXi C&Y Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 13, 2024

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

ShanXi C&Y Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 09, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.50 loss in FY 2022)

ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%

New minor risk - Share price stability

ShanXi C&Y Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Third quarter 2023 earnings released: EPS: CN¥0.043 (vs CN¥0.011 loss in 3Q 2022)

ShanXi C&Y Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: CN¥0.091 loss per share (vs CN¥0.089 loss in 2Q 2022)

New minor risk - Share price stability

ShanXi C&Y Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: CN¥0.009 loss per share (vs CN¥0.007 loss in 1Q 2022)

Insufficient new directors

Now 22% undervalued

Third quarter 2022 earnings released: CN¥0.011 loss per share (vs CN¥0.006 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.089 loss per share (vs CN¥0.022 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.007 loss per share (vs CN¥0.005 profit in 1Q 2021)

ShanXi C&Y Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2021 Results on Apr 29, 2022

Now 23% undervalued

Now 24% undervalued

Second quarter 2021 earnings released: CN¥0.022 loss per share (vs CN¥0.15 loss in 2Q 2020)

ShanXi C&Y Pharmaceutical Group Co., Ltd. (SZSE:300254) and Chen Jinsong entered into an equity transfer agreement to acquire 15.43% stake in Sichuan C&Y Traditional Chinese Medicine Co., Ltd. from Chen Renhu and Tang Wenjing.

First quarter 2021 earnings released: EPS CN¥0.005 (vs CN¥0.21 loss in 1Q 2020)

Full year 2020 earnings released: CN¥1.21 loss per share (vs CN¥0.025 profit in FY 2019)

New 90-day low: CN¥5.57

New 90-day low: CN¥6.67

New 90-day low: CN¥7.27

New 90-day low: CN¥8.01

Third quarter earnings released

First half earnings released

New 90-day high - CN¥8.27

ShanXi C&Y Pharmaceutical Group Co., LTD. to Report First Half, 2020 Results on Aug 27, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령